bisoprolol has been researched along with Disease Models, Animal in 26 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown." | 7.91 | Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure. ( Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H, 2019) |
| "Bisoprolol, an antagonist of β1-adrenergic receptors, is effective in reducing the morbidity and mortality in patients with heart failure (HF)." | 7.83 | β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats. ( Du, Y; Han, K; Huang, X; Ma, A; Wang, T; Wu, G; Xi, Y; Zhang, J, 2016) |
| "In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function." | 7.78 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. ( Bogaards, SJ; de Man, FS; Handoko, ML; Paulus, WJ; Postmus, PE; Schalij, I; van Ballegoij, JJ; van der Velden, J; Vonk-Noordegraaf, A; Westerhof, N, 2012) |
| "Treatment with bisoprolol reversed, to varying degrees, the expression of 10 of the 46 miRNAs whose expression was differentially expressed in the heart failure model." | 5.39 | Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. ( Chen, C; Geng, T; Jin, T; Li, S; Li, X; Ma, A; Sun, C; Wang, T; Yan, H; Zhang, J; Zhang, X, 2013) |
| "Bisoprolol has anti-arrhythmic effects, but its direct effect on I(Na) in cardiac cells remains unclear." | 5.34 | Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure. ( Deng, CY; Kuang, SJ; Tang, HF; Wu, SL; Zhang, WC, 2007) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown." | 3.91 | Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure. ( Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H, 2019) |
| "Bisoprolol, an antagonist of β1-adrenergic receptors, is effective in reducing the morbidity and mortality in patients with heart failure (HF)." | 3.83 | β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats. ( Du, Y; Han, K; Huang, X; Ma, A; Wang, T; Wu, G; Xi, Y; Zhang, J, 2016) |
| "Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle." | 3.79 | Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure. ( Agresta, A; Cannavo, A; de Lucia, C; Femminella, GD; Ferrara, N; Koch, WJ; Komici, K; Leosco, D; Liccardo, D; Pagano, G; Parisi, V; Perrone Filardi, P; Rapacciuolo, A; Rengo, G; Scala, O; Trimarco, B; Zincarelli, C, 2013) |
| "In experimental PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function." | 3.78 | Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. ( Bogaards, SJ; de Man, FS; Handoko, ML; Paulus, WJ; Postmus, PE; Schalij, I; van Ballegoij, JJ; van der Velden, J; Vonk-Noordegraaf, A; Westerhof, N, 2012) |
| "Bisoprolol (60 mg/kg body weight per day) was given 30 min or 14 days after MI or sham operation." | 3.70 | Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size. ( Ertl, G; Gaudron, P; Hu, K, 1998) |
| "Carvedilol, a selective alpha(1) and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia." | 3.70 | Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. ( Chen, J; Christopher, TA; Gao, F; Gu, J; Lopez, BL; Lysko, P; Ma, XL; Ohlstein, EH; Ruffolo, RR; Yue, TL, 2000) |
| "To evaluate the antiarrhythmic efficacy of l-sotalol and bisoprolol on inducible ventricular arrhythmias, conscious dogs with 4- to 8-day-old myocardial infarction were studied by programmed electrical stimulation." | 3.69 | Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol. ( Aidonidis, I; Brachmann, J; Hilbel, T; Kuebler, W; Rizos, I, 1994) |
| "Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle." | 1.40 | Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. ( Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014) |
| "Treatment with bisoprolol reversed, to varying degrees, the expression of 10 of the 46 miRNAs whose expression was differentially expressed in the heart failure model." | 1.39 | Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. ( Chen, C; Geng, T; Jin, T; Li, S; Li, X; Ma, A; Sun, C; Wang, T; Yan, H; Zhang, J; Zhang, X, 2013) |
| " As a patient-friendly, convenient, and multi-day dosing therapeutic system, the transdermal patches incorporating ISDN and BP could be promising for prevention and treatment of hypertension." | 1.34 | A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ( Fu, JH; Kong, SJ; Li, L; Lu, WL; Pei, QL; Shan, Y; Su, CH; Wang, JC; Wang, L; Wang, SM; Wang, Y; Zhang, EH; Zhang, H; Zhang, Q; Zhang, S; Zhang, X; Zhao, JH, 2007) |
| "Bisoprolol has anti-arrhythmic effects, but its direct effect on I(Na) in cardiac cells remains unclear." | 1.34 | Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure. ( Deng, CY; Kuang, SJ; Tang, HF; Wu, SL; Zhang, WC, 2007) |
| "Treatment with bisoprolol prevented the progression of cardiac dysfunction in TO-2 hamsters." | 1.33 | Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. ( Hashimoto, K; Ichihara, G; Ichihara, S; Iwase, M; Kanazawa, H; Kato, Y; Matsushita, A; Oikawa, S; Yamada, Y; Yokota, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Gorosabel, MC | 1 |
| Dubacher, N | 1 |
| Meienberg, J | 1 |
| Matyas, G | 1 |
| Wang, J | 1 |
| Liu, J | 1 |
| Xie, L | 1 |
| Cai, X | 1 |
| Ma, X | 1 |
| Gong, J | 1 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 1 |
| Smirnov, A | 1 |
| Kakehi, K | 1 |
| Iwanaga, Y | 1 |
| Watanabe, H | 1 |
| Sonobe, T | 1 |
| Akiyama, T | 1 |
| Shimizu, S | 1 |
| Yamamoto, H | 1 |
| Miyazaki, S | 1 |
| Li, X | 2 |
| Zhang, X | 2 |
| Wang, T | 2 |
| Sun, C | 1 |
| Jin, T | 1 |
| Yan, H | 1 |
| Zhang, J | 2 |
| Geng, T | 1 |
| Chen, C | 1 |
| Ma, A | 2 |
| Li, S | 1 |
| Rengo, G | 1 |
| Cannavo, A | 1 |
| Liccardo, D | 1 |
| Zincarelli, C | 1 |
| de Lucia, C | 1 |
| Pagano, G | 1 |
| Komici, K | 1 |
| Parisi, V | 1 |
| Scala, O | 1 |
| Agresta, A | 1 |
| Rapacciuolo, A | 1 |
| Perrone Filardi, P | 1 |
| Ferrara, N | 1 |
| Koch, WJ | 1 |
| Trimarco, B | 1 |
| Femminella, GD | 1 |
| Leosco, D | 1 |
| Andersen, S | 1 |
| Schultz, JG | 1 |
| Andersen, A | 1 |
| Ringgaard, S | 1 |
| Nielsen, JM | 1 |
| Holmboe, S | 1 |
| Vildbrad, MD | 1 |
| de Man, FS | 2 |
| Bogaard, HJ | 1 |
| Vonk-Noordegraaf, A | 2 |
| Nielsen-Kudsk, JE | 1 |
| Erokhina, IL | 1 |
| Voronchikhin, PA | 1 |
| Okovityĭ, SV | 1 |
| Emel'ianova, OI | 1 |
| Boivin, V | 1 |
| Beyersdorf, N | 1 |
| Palm, D | 1 |
| Nikolaev, VO | 1 |
| Schlipp, A | 1 |
| Müller, J | 1 |
| Schmidt, D | 1 |
| Kocoski, V | 1 |
| Kerkau, T | 1 |
| Hünig, T | 1 |
| Ertl, G | 2 |
| Lohse, MJ | 1 |
| Jahns, R | 1 |
| Du, Y | 1 |
| Xi, Y | 1 |
| Wu, G | 1 |
| Han, K | 1 |
| Huang, X | 1 |
| Duncker, DJ | 1 |
| Boontje, NM | 1 |
| Merkus, D | 1 |
| Versteilen, A | 1 |
| Krysiak, J | 1 |
| Mearini, G | 1 |
| El-Armouche, A | 1 |
| de Beer, VJ | 1 |
| Lamers, JM | 1 |
| Carrier, L | 1 |
| Walker, LA | 1 |
| Linke, WA | 1 |
| Stienen, GJ | 1 |
| van der Velden, J | 2 |
| Chen, WQ | 1 |
| Cai, H | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Zhang, Y | 1 |
| Suzuki, J | 1 |
| Ogawa, M | 1 |
| Tamura, N | 1 |
| Maejima, Y | 1 |
| Takayama, K | 1 |
| Maemura, K | 1 |
| Honda, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| O-Uchi, J | 1 |
| Lopes, CM | 1 |
| Handoko, ML | 1 |
| van Ballegoij, JJ | 1 |
| Schalij, I | 1 |
| Bogaards, SJ | 1 |
| Postmus, PE | 1 |
| Westerhof, N | 1 |
| Paulus, WJ | 1 |
| Ichihara, S | 1 |
| Yamada, Y | 1 |
| Ichihara, G | 1 |
| Kanazawa, H | 1 |
| Hashimoto, K | 1 |
| Kato, Y | 1 |
| Matsushita, A | 1 |
| Oikawa, S | 1 |
| Yokota, M | 1 |
| Iwase, M | 1 |
| Tahara, K | 1 |
| Saigusa, K | 1 |
| Kagawa, Y | 1 |
| Taguchi, M | 1 |
| Hashimoto, Y | 1 |
| Zhao, JH | 1 |
| Fu, JH | 1 |
| Wang, SM | 1 |
| Su, CH | 1 |
| Shan, Y | 1 |
| Kong, SJ | 1 |
| Wang, Y | 1 |
| Lu, WL | 1 |
| Zhang, H | 1 |
| Zhang, S | 1 |
| Li, L | 1 |
| Zhang, EH | 1 |
| Wang, L | 1 |
| Pei, QL | 1 |
| Wang, JC | 1 |
| Zhang, Q | 1 |
| Tang, HF | 1 |
| Wu, SL | 1 |
| Deng, CY | 1 |
| Zhang, WC | 1 |
| Kuang, SJ | 1 |
| Nishio, M | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Ohtani, T | 1 |
| Takeda, Y | 1 |
| Miwa, T | 1 |
| Hori, M | 1 |
| Masuyama, T | 1 |
| Kondo, T | 1 |
| Yamamoto, K | 1 |
| Aidonidis, I | 1 |
| Rizos, I | 1 |
| Hilbel, T | 1 |
| Kuebler, W | 1 |
| Brachmann, J | 1 |
| Hu, K | 1 |
| Gaudron, P | 1 |
| Gao, F | 1 |
| Chen, J | 1 |
| Lopez, BL | 1 |
| Christopher, TA | 1 |
| Gu, J | 1 |
| Lysko, P | 1 |
| Ruffolo, RR | 1 |
| Ohlstein, EH | 1 |
| Ma, XL | 1 |
| Yue, TL | 1 |
| Matsui, S | 1 |
| Fu, ML | 1 |
26 other studies available for bisoprolol and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Vascular Ehlers-Danlos syndrome: can the beneficial effect of celiprolol be extrapolated to bisoprolol?
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic | 2020 |
Bisoprolol, a β
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiotonic Agents; Disease Models, Ani | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiovascular Agents; Disease Models, | 2019 |
Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiac Volume; Computational Biology; | 2013 |
Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Coronary Circulation; Disease Models, A | 2013 |
Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Bisoprolol | 2014 |
[Reaction of population of pulmonary mast cells in rat bronchial asthma under the effect of β-adrenoreceptor antagonists].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Alcian Blue; Animals; Anti-Asthmat | 2013 |
Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model.
Topics: Animals; Antibodies; B-Lymphocytes; Bisoprolol; CD4-Positive T-Lymphocytes; Disease Models, Animal; | 2015 |
β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atrial Remodeling; Bisoprolol; Cardiotonic Agents; | 2016 |
Prevention of myofilament dysfunction by beta-blocker therapy in postinfarct remodeling.
Topics: Actin Cytoskeleton; Adrenergic beta-Antagonists; Animals; Bisoprolol; Calcium Signaling; Cardiac Myo | 2009 |
Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats?
Topics: Adrenergic Antagonists; Animals; Apoptosis; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dise | 2010 |
A critical role of sympathetic nerve regulation for the treatment of impaired daily rhythm in hypertensive Dahl rats.
Topics: Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Circadian Rhythm; Disease Models, Anim | 2010 |
Combined blockade of β- and α₁-adrenoceptors in left ventricular remodeling induced by hypertension: beneficial or not?
Topics: Adrenergic Antagonists; Animals; Bisoprolol; Carbazoles; Carvedilol; Disease Models, Animal; Humans; | 2010 |
Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Bisoprolol; Disease Models | 2012 |
Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy.
Topics: Aldehydes; Animals; Antioxidants; Bisoprolol; Blood Pressure; Body Weight; Cardiomyopathy, Dilated; | 2006 |
Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure.
Topics: Acute Kidney Injury; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Analysis of Variance; An | 2006 |
A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Biological | 2007 |
Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Aorta, Abdominal; Aortic Coarctation; Arrhythmias, Cardiac; Bisopro | 2007 |
Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats.
Topics: Adrenergic beta-Antagonists; Animals; Bisoprolol; Disease Models, Animal; Dose-Response Relationship | 2008 |
Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol.
Topics: Animals; Bisoprolol; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Female | 1994 |
Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size.
Topics: Adrenergic beta-Antagonists; Animals; Bisoprolol; Body Weight; Disease Models, Animal; Dose-Response | 1998 |
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles | 2000 |
Prevention of experimental autoimmune cardiomyopathy in rabbits by receptor blockers.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; B | 2001 |